Prognostic factors for patients treated with abiraterone

被引：4
作者：
Alvim, Cecilia M. [1 ]
Mansinho, Andre [1 ,2 ]
Paiva, Rita S. [1 ]
Bras, Raquel [1 ]
Semedo, Patricia M. [1 ]
Lobo-Martins, Soraia [1 ]
da Ponte, Carolina B. [3 ]
Macedo, Daniela [1 ]
Ribeiro, Leonor [1 ]
dos Reis, Jose P. [3 ]
Fernandes, Isabel [1 ,2 ]
Costa, Luis [1 ,2 ]
机构：
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Med Oncol, P-1649035 Lisbon, Portugal
[2] Univ Lisbon, Inst Mol Med, Luis Costa Lab, Fac Med, P-1649028 Lisbon, Portugal
[3] Ctr Hosp Univ Lisboa Norte, Dept Urol, Hosp Santa Maria, P-1649035 Lisbon, Portugal
来源：
FUTURE SCIENCE OA | 2020年 / 6卷 / 02期
关键词：
abiraterone acetate; metastatic castration-resistant prostate cancer; prostate-specific antigen response; RESISTANT PROSTATE-CANCER; EARLY PSA RESPONSE; SURVIVAL; ACETATE; SURROGATE;
D O I：
10.2144/fsoa-2019-0079
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Aim: To evaluate prostate-specific antigen response (PSAr) defined as a >= 50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10-0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14-0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA. Lay abstract Therapeutic options for metastatic castration-resistant prostate cancer are expanding. However, biomarkers with predictive and prognostic value to assist in treatment guidance are lacking. The aim of this study was to evaluate prostate-specific antigen response as a prognostic factor in patients treated with abiraterone acetate. It was possible to confirm that prostate-specific antigen response correlated with better overall survival and progression-free survival in this patient cohort, evidencing the possible role of biochemical markers as surrogates for response and prognosis, especially in diseases that are difficult to evaluate radiographically.
引用
收藏
页数：10
相关论文
共 16 条
[1]  
Afshar M, 2015, ANTICANCER RES, V35, P1057
[2]  
[Anonymous], UROL ONCOL, DOI DOI 10.1016/J.UR0L0NC.2012.10.001
[3]  
Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[4]   Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction [J].
Cindolo, Luca ;
Natoli, Clara ;
De Nunzio, Cosimo ;
De Tursi, Michele ;
Valeriani, Maurizio ;
Giacinti, Silvana ;
Micali, Salvatore ;
Rizzo, Mino ;
Bianchi, Giampaolo ;
Martorana, Eugenio ;
Scarcia, Marcello ;
Ludovico, Giuseppe Mario ;
Bove, Pierluigi ;
Laudisi, Anastasia ;
Selvaggio, Oscar ;
Carrieri, Giuseppe ;
Bada, Maida ;
Castellan, Pietro ;
Topazio, Luca ;
Boccasile, Stefano ;
Ditonno, Pasquale ;
Chiodini, Paolo ;
Schips, Luigi .
CLINICAL GENITOURINARY CANCER, 2017, 15 (05) :520-525
[5]   Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival [J].
Facchini, Gaetano ;
Caffo, Orazio ;
Ortega, Cinzia ;
D'Aniello, Carmine ;
Di Napoli, Marilena ;
Cecere, Sabrina C. ;
Della Pepa, Chiara ;
Crispo, Anna ;
Mines, Francesca ;
Ruatta, Fiorella ;
Iovane, Gelsomina ;
Pisconti, Salvatore ;
Montella, Maurizio ;
Berretta, Massimiliano ;
Pignata, Sandro ;
Cavaliere, Carla .
FRONTIERS IN PHARMACOLOGY, 2016, 7
[6]   Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study [J].
Fizazi, Karim ;
Scher, Howard I. ;
Molina, Arturo ;
Logothetis, Christopher J. ;
Chi, Kim N. ;
Jones, Robert J. ;
Staffurth, John N. ;
North, Scott ;
Vogelzang, Nicholas J. ;
Saad, Fred ;
Mainwaring, Paul ;
Harland, Stephen ;
Goodman, Oscar B., Jr. ;
Sternberg, Cora N. ;
Li, Jin Hui ;
Kheoh, Thian ;
Haqq, Christopher M. ;
de Bono, Johann S. .
LANCET ONCOLOGY, 2012, 13 (10) :983-992
[7]   Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors [J].
Fuerea, Alina ;
Baciarello, Giulia ;
Patrikidou, Anna ;
Albiges, Laurence ;
Massard, Christophe ;
Di Palma, Mario ;
Escudier, Bernard ;
Fizazi, Karim ;
Loriot, Yohann .
EUROPEAN JOURNAL OF CANCER, 2016, 61 :44-51
[8]   Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy [J].
Halabi, Susan ;
Armstrong, Andrew J. ;
Sartor, Oliver ;
de Bono, Johann ;
Kaplan, Ellen ;
Lin, Chen-Yen ;
Solomon, Nicole C. ;
Small, Eric J. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) :3944-+
[9]   Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer [J].
Hiroshige, Tasuku ;
Eguchi, Yoshiro ;
Yoshizumi, Osamu ;
Chikui, Katsuaki ;
Kumagai, Hisaji ;
Kawaguchi, Yoshihiro ;
Onishi, Rei ;
Hayashi, Tokumasa ;
Watanabe, Kouta ;
Mitani, Tomotaro ;
Saito, Koujiro ;
Igawa, Tsukasa .
ONCOLOGY LETTERS, 2018, 15 (05) :6806-6814
[10]   Cancer statistics, 2007 [J].
Jemal, Ahmedin ;
Siegel, Rebecca ;
Ward, Elizabeth ;
Murray, Taylor ;
Xu, Jiaquan ;
Thun, Michael J. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66
12